Recente wetenschappelijke publicaties

  • Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.

  • Auteurs Merkel PA, Nair PK, Khalidi N, Terrier B, Hellmich B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Pagnoux C, Specks U, Börjesson Sjö L, Ho CN, Jison M, McCrae C, Necander S, Rodríguez-Suárez E, Shavit A, Walton C, Wechsler ME
  • Auteurs (entité) Roufosse Florence
  • Revue Ann Rheum Dis
  • Date de publication 2025-08
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.
  • Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.

  • Auteurs Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M
  • Auteurs (entité) Bondue Antoine
  • Revue J Am Coll Cardiol
  • Date de publication 2025-08
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.
  • American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

  • Auteurs Mekinian AM, Georgin-Lavaille S, Ferrada MA, Savic S, Koster MJ, Kosmider O, Comont T, Heilblig M, Arostegui JI, Bosco A, Bourguiba R, Calvo KR, Cargo C, Cattaneo C, Chasset F, Coelho H, Campochiaro C, Crisafulli F, Ducharme-Benard S, Faria R, Franceschini F, Frassi M, Groarke EM, Gurnari C, Hakobyan Y, Jamilloux Y, Jurcut C, Kirino Y, Kulasekararaj A, Kunimoto H, Madigan LM, Mann HF, Marvisi C, Milchert M, Morais S, Sockel K, Muratore F, Nakajima H, Patnaik MM, Regadas L, Robin M, Rutgers A, Salvarani C, Sammel AM, Seebach J, Sujobert P, Tomelleri A, Urbanski G, Vandergheynst F, Vieira R, Viswanatha DS, Więsik-Szewczyk E, Diral E, Terrier B, Patel BA, Fenaux P, Grayson PC, Beck DB
  • Auteurs (entité) Vandergheynst Frederic
  • Revue Arthritis Rheumatol
  • Date de publication 2025-08
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.
  • Hypoperfusion intensity ratio is associated with follow-up infarct volume in medium vessel occlusions: A multicenter multinational study.

  • Auteurs Yedavalli V, Salim HA, Lakhani D, Musmar B, Adeeb N, Simonato D, Li YL, Hajjeh O, Essibayi MA, Henninger N, Sundararajan SH, Kühn AL, Khalife J, Ghozy S, Scarcia L, Yeo LL, Tan BY, Regenhardt RW, Heit JJ, Rouchaud A, Fiehler J, Sheth S, Puri AS, Dyzmann C, Colasurdo M, Renieri L, Filipe JP, Harker P, Radu RA, Abdalkader M, Klein P, Ota T, Mowla A, El Naamani K, Jabbour P, Biswas A, Clarençon F, Siegler JE, Nguyen TN, Varela R, Baker A, Altschul D, Gonzalez NR, Möhlenbruch MA, Costalat V, Gory B, Stracke CP, Hecker C, Marnat G, Shaikh H, Griessenauer CJ, Liebeskind DS, Pedicelli A, Alexandre AM, Faizy TD, Tancredi I, Kalsoum E, Lubicz B, Patel AB, Fuschi M, Wintermark M, Guenego A, Dmytriw AA
  • Auteurs (entité) Lubicz Boris
  • Revue Neurotherapeutics
  • Date de publication 2025-08
Hypoperfusion intensity ratio is associated with follow-up infarct volume in medium vessel occlusions: A multicenter multinational study.
  • Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.

  • Auteurs Rossignol P, Zannad F, Massy Z, Azizi M, Chorfa F, Coadic J, Ferreira JP, Saraiva F, Mottier D, Guillemin F, Ngueyon Sime W, Bouali S, Rossignol B, Nortier J, Simon I, Robino C, Davin M, Bataille PM, Chantrel F, Castin N, Esnault V, Kazes I, Hannedouche T, Kamar N, Achard JM, Fenerol C, Achard-Hottelart C, Dimitrov Y, Girerd N, Maucourt-Boulch D, Frimat L
  • Auteurs (entité) Simon Isabelle
  • Revue Lancet
  • Date de publication 2025-08
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Erasme hospital

Erasmeziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasme

Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis